BRNS — Barinthus Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Barinthus Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.268 | 44.7 | 0.802 | 15 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 59.3 | 48.7 | 84.7 | 82.9 | 70.6 |
| Operating Profit | -59 | -4.04 | -83.9 | -68 | -70.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -51.1 | 0.85 | -76.5 | -61.2 | -66.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -51.1 | 5.32 | -73.4 | -61.2 | -66.5 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -50.9 | 5.34 | -73.3 | -61.1 | -66.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -50.9 | 5.34 | -73.3 | -61.1 | -66.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.13 | 0.14 | -1.91 | -1.26 | -1.56 |